Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Kinase inhibitors represent a significant advancement in cancer therapy.
• Sunitinib malate is an oral multi-kinase inhibitor used for renal cell carcinoma and gastrointestinal stromal tumors, with potential in other cancers.
• Sunitinib targets the vascular endothelial growth factor (VEGF) signaling pathway, which is linked to cardiovascular adverse events.

Purpose of the Study:

• To review the incidence and severity of hypertension and heart failure associated with sunitinib.
• To examine findings from other vascular endothelial growth factor (VEGF) signaling inhibitors.
• To explore the mechanisms of sunitinib-induced cardiotoxicity and provide clinical management strategies.

Main Methods:

• Literature review of clinical studies and mechanistic investigations.
• Analysis of adverse event data for sunitinib and related VEGF pathway inhibitors.
• Synthesis of current understanding of cardiotoxicity mechanisms.

Main Results:

• Hypertension is a frequent, generally manageable side effect of sunitinib.
• Heart failure is less common but requires active monitoring and management, and can be reversible.
• Mechanistic understanding suggests proactive hypertension management may prevent severe cardiotoxicity.

Conclusions:

• Vascular endothelial growth factor (VEGF) pathway inhibition by sunitinib can lead to significant cardiovascular adverse events.
• Close monitoring and management of hypertension are crucial for patients treated with sunitinib.
• An attentive clinical approach to managing hypertension may mitigate the risk of severe sunitinib-induced cardiotoxicity.